Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis

Table 1

Patients characteristics.

Characteristics	RA	OA	healthy controls
Patients,	47	42	41
Gender (F/M)	35/12	26/16	31/11
Mean age (years)	58.72 ± 12.05	64.55 ± 11.12	56.07 ± 7.35
CRP (mg/L)	24.23 ± 25.78	3.44 ± 3.53	—
Disease duration (years)	6.81 ± 8.14	7.84 ± 8.79	—
DAS28 score	4.55 ± 1.25	—	—
HAQ score	1.06 ± 0.92	—	—
RF positivity, (%)	28 (60%)	—	—
ACPA positivity, (%)	22 (46%)	—	—
DMARDs/GC	42/32	—	—
Biological therapy	9^*	—	—

ACPA, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; DAS28 score, disease activity score; DMARDs, disease-modifying antirheumatic drugs; F, female; GC, glucocorticoids; HAQ score, Health Assessment Questionnaire score; M, male; OA, osteoarthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joints count. The data are expressed as the mean (±SD).
Out of 9 patients, 6 were treated with anti-TNF therapy, 1 with tocilizumab, 1 with rituximab and 1 with anti-IL-17 therapy.